It’s Just the Beginning

Comply or Stand Your Ground

Pfizer's coronavirus vaccine is APPROVED by regulators for use in UK and could be rolled out across the country NEXT WEEK. This sounds like propaganda!

The Department of Health announced the news just after 7am this morning. It came as England came out of its second national lockdown today. The Pfizer vaccine will reportedly be given staff first due to its short shelf life.

A **Covid-19** vaccine from **Pfizer**/BioNTech has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK - paving the way for mass vaccination to start in just days.

Officials said the vaccine will be made available 'from next week' as Health Secretary Matt Hancock declared 'Help is on its way'.

A Department of Health and Social Care spokesman made the announcement just after 7am this morning as England left its second national lockdown.

Mr. Hancock said: *"Help is on its way. The MHRA has formally authorized the Pfizer/BioNTech vaccine for Covid-19.*

The NHS stands ready to start vaccinating early next week.

The UK is the first country in the world to have a clinically approved vaccine for supply."

The Covid-19 vaccine from Pfizer /BioNTech has been approved by the Regulatory Agency. **They overlooked something and did not tell you that their facilities in China produce the Vaccine! But it is true.** [Full details at the bottom of this article]

An employee at the Pfizer laboratories where they conduct research and development

A priority list of who should get the vaccine first was drawn up earlier this year by the influential Joint Committee on Vaccination and Immunization (JCVI)

A spokesman for the DHSC added: *"The Government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer/BioNTech's Covid-19 vaccine for use.*

This follows months of rigorous clinical trials and a thorough analysis of the data by experts at the MHRA who have concluded that the vaccine has met its strict standards of safety, quality and effectiveness.

The Joint Committee on Vaccination and Immunization (JCVI) will shortly also publish its latest advice for the priority groups to receive the vaccine, including care home residents, health and care staff, the elderly and the clinically extremely vulnerable. 'The vaccine will be made available across the UK from next week."


WHO COULD GET COVID VACCINE FIRST?
Older adults in a care home and care home workers
Anyone 80 and over and health and social care workers, though they may move up the list
75 and over
70 and over
65 and over
High-risk adults under 65 years of age
Moderate-risk adults under 65 years of age
60 and over
55 and over
50 and over
Rest of the population (priority yet to be determined)



A graph showing vaccine orders made by the EU, US, Canada, UK, Japan and Australia. You will get more than one of these vaccines, two or three according to Bill Gates words.



A scientist at the Pfizer lab in New York works on the new vaccine to fight the deadly virus.

Speaking to Sky News Mr. Hancock added there would be *“three modes of delivery' of the vaccine. He explained: 'The first is hospitals themselves, which of course we've got facilities like this. 50 hospitals across the country are already set up and waiting to receive the vaccine as soon as it's approved, so that can now happen.*

Also vaccination centers, which will be big centers where people can go to get vaccinated. They are being set up now."

There will also be a community rollout, including GPs and pharmacists. Now, of course, because of the -70C storage conditions of this vaccine, they will be able to support this rollout where they have those facilities.



"But they'll also be there should the AstraZeneca vaccine be approved because that doesn't have these cold storage requirements and so is operationally easier to roll out." He added: *"We're the first country in the world to have a clinically-authorized vaccine to roll out."*

Just days ago hospitals in England were told to prepare for the rollout of a **Covid-19** vaccine in as soon as 10 days, it has been reported, with **NHS** staff first in line to receive it. The first deliveries of the vaccine created by **Pfizer**/BioNTech were slated to come between December 7 and December 9.

This vaccine, which reported early results suggesting the jab is 95 per cent effective, needs to be stored at extremely low temperatures.

One senior hospital executive had been told to expect the vaccine on December 7 to give to NHS staff during the following week.

On November 20, the Health Secretary said he had formally asked the medicines regulator to assess the Pfizer/BioNTech vaccine for use in the UK.

Matt Hancock hailed it as *“another important step forward in tackling this pandemic'.*

But he said while the regulator's approval would see a rollout ready to start next month, there is “still a long way to go”.

And the MHRA confirmed last Monday it had received the necessary data to progress its review into whether the Pfizer/BioNTech vaccine meets the required standards.

From the moment the Pfizer vaccine leaves the factory in Belgium it can only be taken out of minus -70C four times before it is injected into a patient's arm.

Sir Simon Stevens, chief executive of the NHS in England, said the vaccination programmer would be the *“largest-scale vaccination campaign in our country's history.”*

In a statement, he said: *“This is an important next step in our response to the coronavirus pandemic and hospitals will shortly kick off the first phase of the largest-scale vaccination campaign in our country's history.*

'The NHS has a proven track record of delivering large-scale vaccinations from the winter flu jab to BCG and, once the final hurdles are cleared and the vaccine arrives in England's hospitals, health service staff will begin offering people this ground-breaking jab in a programmer that will expand to cover the whole country in the coming months.”

HOW DO THE OXFORD, MODERNA AND PFIZER/BIONTECH VACCINES COMPARE?

Moderna and Pfizer/BioNTech have both released interim results of the final stage clinical trials of their vaccines, with both suggesting they are extremely effective.

Oxford University has published the findings from its second phase, which show the jab provokes an immune response and is safe to use – it is not yet clear how well it protects against coronavirus in the real world.

Here's how they compare:
CREATOR:
MODERNA (US)
PFIZER (US) & BIONTECH (DE)

OXFORD UNIVERSITY (UK)

How it works:
mRNA vaccine – Genetic material from coronavirus is injected to trick immune system into making 'spike' proteins and learning how to attack them.

mRNA vaccine – both Moderna's and Pfizer and BioNTech's vaccines work in the same way.

Recombinant viral vector vaccine – a harmless cold virus taken from chimpanzees was edited to produce the 'spike' proteins and look like the coronavirus.

How well does it work?
94.5% effective (90 positive in placebo group, 5 positive in vaccine group) .
95% effective (160 positive in placebo group, 8 positive in vaccine group).
62% - 90% effective, depending on dosing.

How much does it cost?
Moderna confirmed it will charge countries placing smaller orders, such as the UK's five million doses, between £24 and £28 per dose. US has secured 100million doses for $1.525billion (£1.16bn), suggesting it will cost $15.25 (£11.57) per dose.

The US will pay $1.95bn (£1.48bn) for the first 100m doses, a cost of $19.50 (£14.80) per dose.

Expected to cost £2.23 per dose. The UK's full 100m dose supply could amount to just £223million.

Can we get hold of it?

UK has ordered five million doses which will become available from March 2021. Moderna will produce 20m doses this year, expected to stay in the US.

UK has already ordered 40million doses, of which 10million could be available in 2020. First vaccinations expected in December.

UK has already ordered 100million doses and is expected to be first in line to get it once approved.

What side effects does it cause?

Moderna said the vaccine is *“generally safe and well tolerated”.* Most side effects were mild or moderate but included pain, fatigue and headache, which were 'generally' short-lived.

Pfizer and BioNTech did not produce a breakdown of side effects but said the Data Monitoring Committee 'has not reported any serious safety concerns'.

Oxford said there have been no serious safety concerns. Mild side effects have been relatively common in small trials, with many participants reporting that their arm hurt after the jab and they later suffered a headache, exhaustion or muscle pain. More data is being collected.

All of the above is a public relations effort to ease the anxiety of those who will be injected with this poison. I do not trust any company where Dr. Anthony Fauci or Microsoft Bill Gates has a vested interest in. Their closets are full of skeletons of those they killed through polio vaccines in Africa, or AZT with the gay community thirty years ago. The reader should be reminded of the so-called Swine Flu vaccine that killed hundreds of thousands. These people are undaunted in their agenda to “Depopulate” the world.

Pfizer / Biontech and Bill Gates / China are
like two couples of swingers in a perpetual orgy
by Silviu "Silview" Costinescu

by Silviu “Silview” Costinescu

Allow me to leak some of their more intimate shots

PharmaTimes online

Search news, articles, e

Magazine Web Exclusives News Competitions Appointments Jobs Business Ir

Free news subscriptions Free RSS feeds

Pfizer to build R&D facility in Wuhan, China

25th November 2009

by Kevin Grogan

Pfizer is expanding its R&D efforts in China and announced plans to build a new facility.

An agreement has been signed to establish a new Pfizer R&D centre in Wuhan, which the firm says represents an expansion of its existing facility in Shanghai. Once the new plant is built, the company expects the number of employees to grow to 200 within three years but gave no details about the financial investment involved.

SOURCE

“

Pfizer Wuhan R&D Center was founded on October 8, 2010, becoming the first world’s top 500 enterprises settled in Wuhan Biolake.

The U.S. Pfizer is transferring its medicine safety business from India to Wuhan, capital of central China’s Hubei, due to the advantages of talent resources and industry environment here.

Five years ago, Pfizer established an affiliate at Wuhan Biolake, a national biological industrial base, and greatly expanded its research and development scale and cooperative sectors in China. The Pfizer Wuhan R&D Center is an important base supporting Pfizer’s global data processing, quality control and medicine safety.

Pfizer has two world class R&D centers in China’s Wuhan and Shanghai, with business operations in over 300 cities. Pfizer’s China Research and Development Center has become one of the company’s seven major R&D centers worldwide.” – government website of the Hubei Province, China

Pfizer looks to Asia and will outsource 30% of manufacturing

3rd December 2007

by PharmaTimes

Pfizer has outlined some of its R&D plans at an investor presentation in Hong Kong, and also announced its intention to double the current levels of its manufacturing outsourcing.

The New York-based drugs giant said that it is looking at contracting out as much as 30% (up from 15%) of its manufacturing to facilities in Asia. Such a move would fit in with the firm's cost-cutting strategy which will see Pfizer cut its worldwide workforce by 10%, or 10,000 jobs, and save $2 billion.

Pfizer Upjohn Becomes First Multinational Drug Company to Open HQ in China

By Teng Jing Xuan / May 30, 2019 05:34 PM / Business & Tech

Photo: IC Photo

Pfizer Upjohn, Pfizer's generic drug unit, opened its global headquarters in Shanghai Thursday, marking the first time any multinational drug company has placed its main office in China, state news agency Xinhua **reported**.

SOURCE

Pfizer China

About Pfizer China

Pfizer's Milestones in China

Pfizer Business in China

Pfizer's Manufacturing Facilities in China

About Pfizer China

Pfizer has a broad and diversified global product portfolio to improve health and well-being at every stage of life

The LeadingForeign Biopharmaceutical Company in China

Launched over 60 innovative drugs in China

Business operations over 300 cities in China

A Market leader in China's cardiovascular and antibiotic market

4 state-of-the-art manufacturing facilities in China

Invested over US$1.5 billion in China to date

2 R&D centers in China

Over 11,000 employees in China

SOURCE

BIONTECH

PRESS RELEASE

BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs

-- Bill & Melinda Gates Foundation invests $55 million in an infectious disease collaboration that could reach up to $100 million in total funding --

Mainz, Germany, September 4, 2019 – BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced today that it has signed an agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to develop HIV and tuberculosis programs, further expanding the Company's infectious disease portfolio. This partnership includes an initial equity investment of $55 million, which is expected to close within the next week. The funds will be used to develop preclinical vaccine and immunotherapy candidates to prevent HIV and tuberculosis infection as well as to lead to durable antiretroviral therapy-free remission of HIV disease. Total funding under the collaboration could reach $100 million through potential future grant funding from the Gates Foundation that would be used to underwrite the evaluation of these candidates in the clinic and support the initiation of new infectious disease projects.

SOURCE (PDF)

msn money
powered by Microsoft News

Search the web (e.g. Goldman Sachs Savings)

Is BioNTech Stock a Buy?

BioNTech has demonstrated the superiority of its science over the past few years. Now, with a partner in Pfizer and a global call to action, both companies appear poised to deliver the vaccine the whole world has been waiting for. With hundreds of millions of doses already pre-sold, a distribution agreement in China, and plans for more than a billion doses next year, BioNTech doesn't seem able to go anywhere but up.

SOURCE

BIONTECH FOSUN PHARMA 复星医药

BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China

- *Phase 1 study will evaluate safety and immunogenicity in Chinese participants to support potential regulatory approval pathway in China*
- *Total of 144 participants to be enrolled in two age groups (18-55 and >55 years)*
- *Trial participants to receive either 10µg or 30µg of BNT162 or a placebo*
- *Clinical supply from BioNTech's GMP-certified mRNA production facilities in Europe*

MAINZ, Germany, and SHANGHAI, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- **BioNTech SE** (Nasdaq: BNTX, "BioNTech" or "the Company") and **Shanghai Fosun Pharmaceutical (Group) Co., Ltd** ("Fosun Pharma" or "Group", Stock Symbol: 600196.SH, 02196.HK), today announced that the first 72 participants have already been dosed with BNT162b1 following IND approval by the Chinese regulatory authority, National Medical Products Administration (NMPA). BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China. The trial is part of BioNTech's global development program aimed at supporting a global supply upon regulatory approval.

The randomized, placebo-controlled, observer-blinded Phase 1 clinical trial in China will enroll 144 healthy subjects to evaluate the safety and immunogenicity of the vaccine as well as to confirm dose selection. The first group of subjects immunized in Stage 1 of the study will be healthy adults aged 18 to 55 years, followed by elderly healthy participants (>55 years). As part of the two-dose cohort design, subjects will receive two injections (prime-boost), 21 days apart, of 10µg or 30µg of the vaccine candidate or placebo. The dose range selection was determined based on early data from clinical trials conducted in Germany and the United States. The participants will be dosed in Taizhou Clinical Phase1 Center, Jiangsu province.

SOURCE

PHARMABIZ.com
india's most comprehensive pharma portal

Search Here

About us | Contact us | Advert

Home | Editorial | Services | Interview | Q&A | Chronicle Specials | Pharma Mart | ePharmail | Archives

Home > News

you can get e-magazine links on WhatsApp Click here

Biotechnology

+ Font Resize -

BioNTech inks agreement with Gates Foundation to develop HIV and TB programmes

Mainz, Germany
Friday, September 6, 2019, 09:00 Hrs [IST]

BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, has signed an agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to develop HIV and tuberculosis programmes, further expanding the Company's infectious disease portfolio. This partnership includes an initial equity investment of $55 million, which is expected to close within the next week. The funds will be used to develop preclinical vaccine and immunotherapy candidates to prevent HIV and tuberculosis infection as well as to lead to durable antiretroviral therapy-free remission of HIV disease.

Total funding under the collaboration could reach $100 million through potential future grant funding from the Gates Foundation that would be used to underwrite the evaluation of these candidates in the clinic and support the initiation of new infectious disease projects.

"We are thrilled about the partnership with the Gates Foundation and the outstanding network of infectious disease specialists that it has built," said Prof. Ugur Sahin, CEO of BioNTech. "Targeting severe infectious diseases such as tuberculosis and HIV infection is in line with our mission to leverage our immunotherapy capabilities not only for cancer but also beyond, in disease areas of high medical need."

SOURCE

Leaked documents show China bluntly lied about Covid-19 and mishandled early pandemic

Reuters describes BioNTech Chief Executive Ugur Sahin as the son of a Turkish immigrant working at a Ford factory in Cologne. He now figures among the 100 richest Germans, together with his wife and fellow board member Oezlem Tuereci according to weekly Welt am Sonntag.

Azerbaijani forces enter last district handed over by Armenia

The market value of Nasdaq-listed BioNTech, which the pair co-founded, had ballooned to $21 billion as of Friday's close from $4.6 billion a year ago, with the firm set to play a major role in mass immunisation against the coronavirus.

Sahin has, however, maintained his humility, as he typically walks into business meetings wearing jeans and carrying his signature bicycle helmet and backpack with him.

SOURCE

South China Morning Post News' Comment Lifestyle More + US-China Relations

Business

Fosun Pharma stock surges on prospect of Covid-19 vaccine launch in China, after German partner BioNTech's clinical success

- 'A victory for science, a victory for global cooperation,' says Guo Guangchang, the billionaire chairman of majority shareholder Fosun International
- Fosun Pharma has a deal with Hong Kong-listed pharmaceutical distributor Jacobson Pharma for potentially supplying 10 million doses to Hong Kong and Macau

Eric Ng

Published: 2:15pm, 10 Nov, 2020

Why you can trust SCMP

SOURCE



BILL & MELINDA GATES foundation

Search gatesfoundation

HOW WE WORK

GRANT

← BACK

Print

Pfizer Inc.

Date: September 2016
Purpose: to support development of a Group B streptococcus (GBS) vaccine for developing country access
Amount: $17,252,854
Term: 68
Topic: Pneumonia, Research and Learning Opportunities
Regions Served: GLOBAL|AFRICA|EUROPE|NORTH AMERICA
Program: Global Health
Grantee Location: New York, New York
Grantee Website: http://www.pfizer.com/

News | USA | UK | Russia & FSU | Op-ed | Sport | Business

ALSO ON RT.COM

Round up the 'anti-vaxxers'? Enlist religious leaders? Bill Gates warns US needs to brainstorm ways to reduce 'vaccine hesitancy'

Pharma giant Pfizer earlier this week declared that its Covid-19 vaccine – heavily funded by Gates – was 90 percent effective, though the company has not released the results of its clinical trials and some medical experts are skeptical due to the small sample size and absence of details surrounding any aspect of the supposedly successful trial. The billionaire hinted back in September that Pfizer would be the first drugmaker to seek emergency FDA authorization for its jab, which has been developed in partnership with BioNTech. The company's jab relies on an mRNA mechanism to trigger an immune response, a model that has never been used in any other vaccine approved for human consumption.

While the UK's National Health Service is already winding up its military to deliver the Pfizer shot and the US has also declared its military will be on standby to deliver the Covid-19 jab before the end of the year, no western country has yet approved a vaccine against the coronavirus. Russia's Sputnik V vaccine has received emergency authorization and its manufacturer has begun filling orders outside the country, while multiple Chinese vaccine candidates have also received emergency authorization.

SOURCE

World Economic Forum
3h ·

A dose of hope?

WEFORUM.ORG

'Great day for humanity': Pfizer says COVID-19 vaccine over 90% effective

You and 1.1K others 300 Comments 144 Shares

Haha Comment Share

Silview.media When the people who created and financed Covidiocracy recommend you the cure for Covidiocracy, you take it and burn it. Then the factories.
https://silview.media/.../wef-lockdown-worlds-biggest.../

SILVIEW.MEDIA

WEF to your face: "Lockdown is the world's biggest psychological…

All of the named participants in this “Depopulation” agenda have past records of corruption, criminal activities, individuals who at one time or another have been involved in bioweapons creation and killing infinite numbers of unsuspecting innocent third-world countries. As an example, on December 2, 2020, a report appeared in the news media on the Internet that stated 40% of health workers did not plan to take the alleged Covid-19 vaccine! I tried to save it but in a second my AOL slammed it with the red circled X, stating that this page could not be saved. What does that tell you? It reflects the media applying censorship of the narrative story. It merely confirms what I have said throughout this year. THIS IS A “DEPOPULATION AGENDA”, and it was planned a long time ago. That was revealed in a previous article, showing their strategy and agenda. I will attach that saved page below. A former CEO of Pfizer one headed up the U.S. Military biological warfare program.



A larger copy for the reader who wants to print and share appears below on the next page. My major source of proof is their own words, statements, actions, and documents which all confirm that since the founding of the Club of Rome in 1968, their agenda has been “Depopulation” since 1972!

Whether it be Bill Cooper’s book, ‘Behold A Pale Horse’ or the document found on an old IBM copier bought for scrap which had a copy of the Bilderberg presentation, ‘Silent Weapons for Quiet Wars’ , and so many other speeches, interviews, news reports, we have forty years of evidence that indicts them all. Read my series on “Depopulation”

THE TEST IS THE VACCINE! DO NOT GET TESTED, NO MATTER WHAT!

Nanoparticles for nasal vaccination

Noemi Csaba et al. Adv Drug Deliv Rev 2009.

Abstract

The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance. The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.

@THELIBCOMMIE

Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery

Abstract

Over the past few years, nasal drug delivery has attracted more and more attentions, and been recognized as the most promising alternative route for the systemic medication of drugs limited to intravenous administration. Many experiments in animal models have shown that nanoscale carriers have the ability to enhance the nasal delivery of peptide/protein drugs and vaccines compared to the conventional drug solution formulations. However, the rapid mucociliary clearance of the drug-loaded nanoparticles can cause a reduction in bioavailability percentage after intranasal administration. Thus, research efforts have considerably been directed towards the development of hydrogel nanosystems which have mucoadhesive properties in order to maximize the residence time, and hence increase the period of contact with the nasal mucosa and enhance the drug absorption. It is most certain that the high viscosity of hydrogel-based nanosystems can efficiently offer this mucoadhesive property. This update review discusses the possible benefits of using hydrogel polymer-based nanoparticles and hydrogel nanocomposites for drug/vaccine delivery through the intranasal administration.

Nasal vaccine innovation

Abstract

The current vaccine market is gaining momentum in the development of alternative administration routes, namely intranasal, oral, topical, pulmonary, vaginal, and rectal; the nasal route offers the most promising opportunity for vaccine administration. It can enhance convenience, safety, elicit both local and systemic immune responses; thus potentially provide protection from pathogens at the site of entry. Nasal vaccine innovation comes with both opportunities and challenges. The innovative strategies used by industry and researchers to overcome the hurdles are discussed in this article: these include live-attenuated vaccines, adjuvants, mucoadhesives, particulate delivery systems, virus-like particles, vaccine manufacture, challenges of regulatory authorities, and the nasal vaccine impact on market potential. Critical issues for effective nasal vaccination are the antigen-retention period that enables its interaction with the lymphatic system and choice of an adjuvant that is nontoxic and induces the required immune response. Co-adjuvanting by means of a mucoadhesive technology addresses some of these issues. ChiSys(®), a natural bioadhesive with proven intranasal safety profile, has already demonstrated efficacy for several nasally delivered vaccines including norovirus. With the looming threat of a pandemic, alternatives such as intranasal vaccination will ultimately facilitate greater public compliance and rapid mass global vaccination.

AND THERE WILL BE MUCH GREATED "PUBLIC COMPLIANCE" WHEN THE PUBLIC IS BEING TOLD THEY'RE TAKING A TEST AND NOT A VACCINE, AND THEY MUST TAKE THIS "TEST" IN ORDER TO GO TO WORK, SCHOOL, ETC...

Jesus Christ in Matthew 24 & 25 spoke specific words about being deceived in the End Times, and that is where we are at the present. Spiritual discernment tells us that none of this is for our good. **Jesus** told us to be on guard and to be careful so that no man **would deceive** us; and he tells us that much of the **deception would** come from people who **would** be using His name and even some people **would** be so deceived they **would** literally claim to be Christ, Himself. **Jesus**, **said deception would** come from two sources: People who **would** come in His name.

Jesus spoke about a time to come when the deception will be especially great when false messiahs and false prophets will appear. Even the people of God could be deceived if it were not for God's providential protection: ***"For false messiahs and false prophets will appear and perform great signs and wonders to deceive, if possible, even the elect"*** (Matthew 24:24, see also Mark 13:5–6, Luke 21:8).

All of these deceptions are instigated by the devil. However, 2nd Thessalonians 2:11 also speaks of the deception as God's punishment on people who refuse to believe the truth. The context seems to be similar to that of the gospel passages above and speaks of one to come who will be especially deceptive: "The coming of the lawless one is by the activity of Satan with all power and false signs and wonders, and with all wicked deception for those who are perishing, because they refused to love the truth and so be saved. Therefore God sends them a strong delusion, so that they may believe what is false, in order that all may be condemned who did not believe the truth but had pleasure in unrighteousness" (2 Thessalonians 2:9–12, ESV).

Since Pfizer is the focus of this article, the reader might find this article very interesting.

Head of Pfizer Research: Covid Vaccine is Female Sterilization
Health & Money News

The vaccine contains a **spike protein (see image) called syncytin-1**, vital for the formation of human placenta in women. If the vaccine works so that we form an immune response AGAINST the spike protein, we are also **training the female body to attack syncytin-1,** which could lead to infertility in women of an unspecified duration.



Dr. Wodarg and Dr. Yeadon request a stop of all corona vaccination studies and call for co-signing the petition.

On December 1, 2020, the ex-Pfizer head of respiratory research **Dr. Michael Yeadon** and the lung specialist and former head of the public health department **Dr. Wolfgang Wodarg** filed an application with the EMA, the European Medicine Agency responsible for EU-wide drug approval, for the **immediate suspension of all SARS CoV 2 vaccine studies, in particular the BioNtech/Pfizer study on BNT162b (EudraCT number 2020-002641-42).**

Dr. Wodarg and Dr. Yeadon demand that the studies – for the protection of the life and health of the volunteers – should not be continued until a study design is available that is suitable to address the **significant safety concerns** expressed by an increasing number of renowned scientists against the vaccine and the study design.

StarGate TV Series Warned Us In 2001 About the Vaccination Disaster Facing Us Today

On the one hand, the petitioners demand that, due to the known lack of accuracy of the PCR test in a serious study, a so-called **Sanger sequencing** must be used. This is the only way to make reliable statements on the effectiveness of a vaccine against Covid-19. On the basis of the many different PCR tests of highly varying quality, **neither the risk of disease nor a possible vaccine benefit can be determined with the necessary certainty**, which is why testing the vaccine on humans is unethical per se.

Furthermore, they demand that it must be excluded, e.g. by means of animal experiments, **that risks already known from previous studies**, which partly originate from the nature of the corona viruses, **can be realized**. The concerns are directed in particular to the following points:

- The formation of so-called **"non-neutralizing antibodies"** can lead to an exaggerated immune reaction, especially when the test person is confronted with the real, "wild" virus after vaccination. This so-called **antibody-dependent amplification, ADE**, has long been known from experiments with corona vaccines in cats, for example. In the course of these studies all cats that initially tolerated the vaccination well died after catching the wild virus.
- The vaccinations are expected to produce antibodies against spike proteins of SARS-CoV-2. However, spike proteins also contain **syncytin-homologous proteins**, which are essential for the formation of the placenta in mammals such as humans. It must be absolutely ruled out that a vaccine against SARS-CoV-2 could trigger an immune reaction against syncytin-1, as otherwise **infertility of indefinite duration could result in vaccinated women**.
- The mRNA vaccines from BioNTech/Pfizer contain **polyethylene glycol (PEG)**. 70% of people develop antibodies against this substance – this means that many people can develop allergic, potentially fatal reactions to the vaccination.
- The much too short duration of the study does **not allow a realistic estimation of the late effects**. As in the narcolepsy cases after the swine flu vaccination, millions of healthy people would be exposed to an unacceptable risk if an emergency approval were to be granted and the possibility of observing the late effects of the vaccination were to follow. Nevertheless, BioNTech/Pfizer apparently submitted an application for emergency approval on December 1, 2020.

CALL FOR HELP: Dr. Wodarg and Dr. Yeadon ask as many EU citizens as possible to co-sign their petition by sending the e-mail prepared here to the EMA.



10 Years Ago Who Faked A Pandemic

Vaccines have helped mankind to tackle the dire threat of infectious disease for more than a hundred years.

They have become key tools of public health and scientists are charged with developing them as quickly as possible to combat the emergence of new diseases such as Zika, SARS, Ebola and Coronavirus.

But why are growing numbers of parents all over the world now questioning the wisdom of having their children vaccinated? Why have public-sector vaccine producers been sold off?

And can we trust the multinational corporations that increasingly dominate vaccine development and production?

In this controversial book renowned author Stuart Blume discloses that many of the most influential advisers, at both World Health Organization (WHO) and national levels, are paid consultants to the vaccine industry raising a very serious question – that the WHO might be working for the vaccine industry's interests and not the people – the reason why 10 years ago WHO faked a pandemic.

In recent years, there have been more and more warnings that a pandemic as deadly as that of 1918 is imminent.

In 2009 HIN1, the strain that really worries virologists, returned. Though it was an HINI virus, it was not identical to the HIN1 virus involved in the 1976 ‘epidemic’.

Analysis showed that it was a new strain of H1N1, formed by an existing blend (the proper term is ‘reassortment’) of bird, swine and human flu viruses, further combined with a pig flu virus, thus leading to the term ‘swine flu’.

The virus seems to have emerged in Veracruz, in Mexico, which is why it also acquired the name ‘Mexican flu’.

The Mexican government closed down most of the city’s public facilities in an attempt to halt the spread of the virus, but it nevertheless spread around the world.

Unlike most strains of influenza, and to the surprise of epidemiologists, this virus was found disproportionately to infect younger adults rather than the elderly.

In June 2009 the WHO declared the outbreak to be a pandemic. This decision was based not on advice from its permanent vaccine advisory committee (known as the Strategic Advisory Group of Experts, or SAGE), but on the advice of an emergency committee, the names of whose members were not made public at the time.

The announcement of a pandemic automatically triggered the conditional orders for vaccine that rich countries had already placed with vaccine manufacturers.

The governments of many European countries ordered two doses for every inhabitant, amounting to hundreds of millions of doses, costing hundreds of millions of euros.

Fortunately, or unfortunately, by the time the bulk of the vaccine orders had been delivered the number of cases was already tapering off.

In the summer of 2010 the WHO announced that the pandemic had ended. The virus had been far less deadly than experts had predicted. Estimates of how many people died from this HINI epidemic vary widely (from ten thousand to some hundreds of thousands) and have been disputed.

What does seem clear is that most deaths occurred not in Europe but in Africa and Southeast Asia. In the event, most of the vaccine was unused, as it had been bought by the world’s more affluent countries and had often arrived when the epidemic was past its high point.

Countries that had not been able to push themselves to the front of the queue no longer had an interest in purchasing surplus vaccine.

Millions of doses, which would be of no value in combatting a future influenza epidemic (and which some critics claimed had not been properly tested for safety) had to be destroyed. They were sold to naïve third-world countries, even by bribing their national

leaders. The WHO is as corrupt as the CDC, NIAID, and NIH. Their credibility does not exist and people have short memories of the crimes committed over the past twenty years with fake virus epidemics.

Fierce debate followed, with critics claiming that the WHO had exaggerated the danger, spreading fear and confusion' rather than 'immediate information'. Committees of enquiry were appointed to investigate decision-making at the WHO and national levels.

On what basis, and on whose advice, had the pandemic been declared? On what basis and on whose advice had national health authorities signed secret contracts with multinational vaccine manufacturers?

When it finally became known that many of the most influential advisers, at both WHO and national levels, were paid consultants to the vaccine industry, many commentators were appalled. Whose interests had they been serving? Wasn't this a clear case of conflict of interests? CBS 60-Minutes even did an expose on this Swine Flu fraud in 1976! It aired once but was subsequently buried in the memory hole!

Hot News!

Share this: Walmart is gonna crash? $100M+ each (3 Walton) owner SOLD stock shares. It is more likely that a stock market crash is coming very soon! What do they know that you don't know! Get ready folks, we are going up ↗.

11/23/20 Walton, S Robson
Director and Beneficial O… Sale 260,000 149.94 – 151.88 1,391,314,590 $39.1 M
Walton, Alice L
Beneficial Owner of more … Sale 260,000 149.94 – 151.88 1,398,807,179 $39.1 M
Walton, Jim C
Beneficial Owner of more … Sale 260,000 149.94 – 151.88 1,394,485,123 $39.1 M

11/20/20 Walton, S Robson
Director and Beneficial O… Sale 450,000 150.22 – 152.23 1,391,674,590 $67.9 M
Walton, Alice L
Beneficial Owner of more … Sale 450,000 150.22 – 152.23 1,399,717,179 $67.9 M
Walton, Jim C
Beneficial Owner of more … Sale 450,000 150.22 – 152.23 1,394,745,123 $67.9 M
^ ^ ^ ^
Shares Price Range Transaction# $$$Amt.

I have been watching insider activity in the stock market for some now and these three are just the latest of corporate owners selling while the market has been pumped to collapse!!!!

Blessings in Jesus Name,

Pastor Bob, EvanTeachr@aol.com
www.pastorbobreid.com
http://jesusisthewaythetruththelife.ocm/node/22